Physician profile
Robert C Frere
NPI 1669567095
$41,885.60
in general payments reported to CMS, 2019-2025
36 companies · $1,481 in 2025
The $1,481 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $6,063 · 2021: $3,303 · 2022: $3,117 · 2023: $2,716 · 2024: $1,305 · 2025: $1,481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,348 · Consulting Fee: $150 · Education: $4.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,348.38 |
| Consulting Fee | $150.00 |
| Education | $4.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $15,713.85 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Genentech USA, INC. | $8,896.90 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Allergan, INC. | $6,408.37 | 2020-2021 | |
| Emd Serono, INC. | $1,861.22 | 2022-2025 | Mavenclad |
| Genentech, INC. | $1,756.61 | 2021-2023 | Ocrevus |
| Teva Pharmaceuticals USA, INC. | $943.10 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Alexion Pharmaceuticals, INC. | $744.13 | 2019-2024 | Ultomiris, Soliris |
| Tg Therapeutics, INC. | $650.27 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $589.87 | 2019-2025 | |
| Argenx US, INC. | $559.99 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Neurelis, INC. | $447.43 | 2021-2025 | Valtoco |
| Avanir Pharmaceuticals, INC. | $348.33 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $275.69 | 2019-2023 | Nuplazid |
| Horizon Therapeutics Plc | $231.23 | 2023 | Uplizna |
| Lundbeck LLC | $226.04 | 2023-2025 | Vyepti |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $221.53 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $209.40 | 2023-2025 | Ingrezza, Ongentys |
| Amgen INC. | $202.07 | 2022-2025 | Uplizna |
| Ucb, INC. | $187.72 | 2022-2025 | Rystiggo |
| Janssen Pharmaceuticals, INC | $169.98 | 2022 | |
| Genzyme Corporation | $169.27 | 2019-2022 | |
| Sk Life Science, INC. | $166.30 | 2021-2023 | Xcopri |
| Biohaven Pharmaceutical Holding Company LTD. | $124.99 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $124.99 | 2024 | Wainua |
| Biohaven Pharmaceuticals, INC. | $120.62 | 2021 | |
| Livanova USA, INC. | $103.97 | 2020-2022 | |
| Life Molecular Imaging LTD | $95.80 | 2024 | Neuraceq |
| Mdd US Operations, LLC | $70.63 | 2020 | |
| Merz Pharmaceuticals, LLC | $65.95 | 2023 | Xeomin |
| Sunovion Pharmaceuticals INC. | $59.72 | 2020-2022 | |
| Akcea Therapeutics, INC. | $38.23 | 2019 | |
| Sumitomo Pharma America, INC. | $23.01 | 2023 | Aptiom |
| Avion Pharmaceuticals | $21.92 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.94 | 2025 | Hyqvia |
| Otsuka America Pharmaceutical, INC. | $19.21 | 2023 | Nuedexta |
| Cala Health, INC. | $16.32 | 2023 | Cala Trio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Frere listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.